메뉴 건너뛰기




Volumn 8, Issue 7, 2013, Pages

When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

EID: 84879898937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069462     Document Type: Article
Times cited : (25)

References (59)
  • 1
    • 0017347943 scopus 로고
    • Foundations of cost-effectiveness analysis for health and medical practices
    • doi:10.1056/NEJM197703312961304. PubMed: 402576
    • Weinstein MC, Stason WB, (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716-721. doi:10.1056/NEJM197703312961304. PubMed: 402576.
    • (1977) N Engl J Med , vol.296 , pp. 716-721
    • Weinstein, M.C.1    Stason, W.B.2
  • 2
    • 33644863151 scopus 로고    scopus 로고
    • Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems)
    • PubMed: 16673675
    • Hutton J, McGrath C, Frybourg JM, Tremblay M, Bramley-Harker E, et al. (2006) Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). Int J Technol Assess Health Care. 22: 10-18. PubMed: 16673675.
    • (2006) Int J Technol Assess Health Care , vol.22 , pp. 10-18
    • Hutton, J.1    McGrath, C.2    Frybourg, J.M.3    Tremblay, M.4    Bramley-Harker, E.5
  • 3
    • 77953018037 scopus 로고    scopus 로고
    • A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006
    • doi:10.1177/0272989X09360066
    • Greenberg D, Rosen AB, Wacht O, Palmer J, Neumann PJ, (2010) A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. Med Decis Mak. 30: 320-327. doi:10.1177/0272989X09360066.
    • (2010) Med Decis Mak , vol.30 , pp. 320-327
    • Greenberg, D.1    Rosen, A.B.2    Wacht, O.3    Palmer, J.4    Neumann, P.J.5
  • 4
    • 33645505995 scopus 로고    scopus 로고
    • Bias in published cost effectiveness studies: systematic review
    • doi:10.1136/bmj.38737.607558.80. PubMed: 16495332
    • Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, et al. (2006) Bias in published cost effectiveness studies: systematic review. BMJ. 332: 699-703. doi:10.1136/bmj.38737.607558.80. PubMed: 16495332.
    • (2006) BMJ , vol.332 , pp. 699-703
    • Bell, C.M.1    Urbach, D.R.2    Ray, J.G.3    Bayoumi, A.4    Rosen, A.B.5
  • 5
    • 11844271509 scopus 로고    scopus 로고
    • Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study
    • doi:10.1136/bmj.38285.482350.82. PubMed: 15601681
    • Miners AH, Garau M, Fidan D, Fischer AJ, (2005) Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ. 330: 65. doi:10.1136/bmj.38285.482350.82. PubMed: 15601681.
    • (2005) BMJ , vol.330 , pp. 65
    • Miners, A.H.1    Garau, M.2    Fidan, D.3    Fischer, A.J.4
  • 6
    • 34247501840 scopus 로고    scopus 로고
    • Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups
    • PubMed: 17234022
    • Chauhan D, Miners AH, Fischer AJ, (2007) Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups. Int J Technol Assess Health Care. 23: 96-100. PubMed: 17234022.
    • (2007) Int J Technol Assess Health Care , vol.23 , pp. 96-100
    • Chauhan, D.1    Miners, A.H.2    Fischer, A.J.3
  • 7
    • 78049440721 scopus 로고    scopus 로고
    • Modeling in pharmacoeconomic studies: funding sources and outcomes
    • doi:10.1017/S0266462310000322. PubMed: 20584363
    • Garattini L, Koleva D, Casadei G, (2010) Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 26: 330-333. doi:10.1017/S0266462310000322. PubMed: 20584363.
    • (2010) Int J Technol Assess Health Care , vol.26 , pp. 330-333
    • Garattini, L.1    Koleva, D.2    Casadei, G.3
  • 8
    • 34347243202 scopus 로고    scopus 로고
    • Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
    • doi:10.1371/journal.pmed.0040184. PubMed: 17550302
    • Bero L, Oostvogel F, Bacchetti P, Lee K, (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLOS Med 4: e184. doi:10.1371/journal.pmed.0040184. PubMed: 17550302.
    • (2007) PLOS Med , vol.4
    • Bero, L.1    Oostvogel, F.2    Bacchetti, P.3    Lee, K.4
  • 9
    • 33646679623 scopus 로고    scopus 로고
    • Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005
    • doi:10.1001/jama.295.19.2270. PubMed: 16705108
    • Ridker PM, Torres J, (2006) Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA. 295: 2270-2274. doi:10.1001/jama.295.19.2270. PubMed: 16705108.
    • (2006) JAMA , vol.295 , pp. 2270-2274
    • Ridker, P.M.1    Torres, J.2
  • 10
    • 0043198131 scopus 로고    scopus 로고
    • Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
    • doi:10.1001/jama.290.7.921. PubMed: 12928469
    • Als-Nielsen B, Chen W, Gluud C, Kjaergard LL, (2003) Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 290: 921-928. doi:10.1001/jama.290.7.921. PubMed: 12928469.
    • (2003) JAMA , vol.290 , pp. 921-928
    • Als-Nielsen, B.1    Chen, W.2    Gluud, C.3    Kjaergard, L.L.4
  • 11
    • 0037014942 scopus 로고    scopus 로고
    • Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ
    • doi:10.1136/bmj.325.7358.249. PubMed: 12153921
    • Kjaergard LL, Als-Nielsen B, (2002) Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ. 325: 249. doi:10.1136/bmj.325.7358.249. PubMed: 12153921.
    • (2002) BMJ , vol.325 , pp. 249
    • Kjaergard, L.L.1    Als-Nielsen, B.2
  • 12
    • 10744230594 scopus 로고    scopus 로고
    • Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials
    • PubMed: 14970094
    • Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, et al. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 170: 477-480. PubMed: 14970094.
    • (2004) CMAJ , vol.170 , pp. 477-480
    • Bhandari, M.1    Busse, J.W.2    Jackowski, D.3    Montori, V.M.4    Schünemann, H.5
  • 13
    • 0029018670 scopus 로고
    • Manufacturing consensus, marketing truth: guidelines for economic evaluation
    • doi:10.7326/0003-4819-123-1-199507010-00010. PubMed: 7762917
    • Evans RG, (1995) Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 123: 59-60. doi:10.7326/0003-4819-123-1-199507010-00010. PubMed: 7762917.
    • (1995) Ann Intern Med , vol.123 , pp. 59-60
    • Evans, R.G.1
  • 14
    • 49949104757 scopus 로고    scopus 로고
    • SLCO1B1 variants and statin-induced myopathy--a genomewide study
    • doi:10.1056/NEJMoa0801936. PubMed: 18650507, SEARCH Collaborative Group
    • SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman Let al. (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 359: 789-799. doi:10.1056/NEJMoa0801936. PubMed: 18650507.
    • (2008) N Engl J Med , vol.359 , pp. 789-799
    • Link, E.1    Parish, S.2    Armitage, J.3    Bowman, L.4
  • 15
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
    • doi:10.1016/S0140-6736(09)61965-6. PubMed: 20167359
    • Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 375: 735-742. doi:10.1016/S0140-6736(09)61965-6. PubMed: 20167359.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3    Welsh, P.4    Buckley, B.M.5
  • 16
    • 84864832599 scopus 로고    scopus 로고
    • The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
    • Cholesterol Treatment Trialists' (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380: 581-90.
    • (2012) Lancet , vol.380 , pp. 581-590
  • 17
    • 79960389336 scopus 로고    scopus 로고
    • Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era
    • doi:10.1161/CIR.0b013e318227720f. PubMed: 21709063
    • Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L, (2011) Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 124: 146-153. doi:10.1161/CIR.0b013e318227720f. PubMed: 21709063.
    • (2011) Circulation , vol.124 , pp. 146-153
    • Lazar, L.D.1    Pletcher, M.J.2    Coxson, P.G.3    Bibbins-Domingo, K.4    Goldman, L.5
  • 19
    • 84859531777 scopus 로고    scopus 로고
    • Healthy men should not take statins
    • doi:10.1001/jama.2012.423. PubMed: 22496261
    • Redberg RF, Katz MH, (2012) Healthy men should not take statins. JAMA. 307: 1491-1492. doi:10.1001/jama.2012.423. PubMed: 22496261.
    • (2012) JAMA , vol.307 , pp. 1491-1492
    • Redberg, R.F.1    Katz, M.H.2
  • 20
    • 84869432250 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692
    • Newman DH, Saini V, Brody H, Brownlee S, Hoffman JR, et al. (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1814. doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692.
    • (2012) Lancet , vol.380 , pp. 1814
    • Newman, D.H.1    Saini, V.2    Brody, H.3    Brownlee, S.4    Hoffman, J.R.5
  • 21
    • 84869432250 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692
    • Donzelli A, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1814-1815. doi:10.1016/S0140-6736(12)62020-0. PubMed: 2317769323177692.
    • (2012) Lancet , vol.380 , pp. 1814-1815
    • Donzelli, A.1
  • 22
    • 84869416480 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694
    • Battaggia A, Font M, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1815. doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694.
    • (2012) Lancet , vol.380 , pp. 1815
    • Battaggia, A.1    Font, M.2
  • 23
    • 84869416480 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694
    • Simpson WG, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1815-1816. doi:10.1016/S0140-6736(12)62023-6. PubMed: 2317769523177694.
    • (2012) Lancet , vol.380 , pp. 1815-1816
    • Simpson, W.G.1
  • 24
    • 84869426457 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696
    • Mascitelli L, Goldstein MR, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1816. doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696.
    • (2012) Lancet , vol.380 , pp. 1816
    • Mascitelli, L.1    Goldstein, M.R.2
  • 25
    • 84869426457 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696
    • Ray KK, Redberg RF, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1816. doi:10.1016/S0140-6736(12)62025-X. PubMed: 2317769723177696.
    • (2012) Lancet , vol.380 , pp. 1816
    • Ray, K.K.1    Redberg, R.F.2
  • 26
    • 84869410853 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62027-3. PubMed: 23177699
    • Zomer E, Owen AJ, Magliano DJ, Reid CM, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1817. doi:10.1016/S0140-6736(12)62027-3. PubMed: 23177699.
    • (2012) Lancet , vol.380 , pp. 1817
    • Zomer, E.1    Owen, A.J.2    Magliano, D.J.3    Reid, C.M.4
  • 27
    • 84869461894 scopus 로고    scopus 로고
    • Statins for people at low risk of cardiovascular disease
    • doi:10.1016/S0140-6736(12)62029-7. PubMed: 23177700
    • Wald N, Law M, (2012) Statins for people at low risk of cardiovascular disease. Lancet. 380: 1818. doi:10.1016/S0140-6736(12)62029-7. PubMed: 23177700.
    • (2012) Lancet , vol.380 , pp. 1818
    • Wald, N.1    Law, M.2
  • 28
    • 68049122102 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • PRISMA Group
    • Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6: e1000097.
    • (2009) PLOS Med , vol.6
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 29
    • 84861757517 scopus 로고    scopus 로고
    • Financial relationships in economic analyses of targeted therapies in oncology
    • doi:10.1200/JCO.2011.38.6078. PubMed: 22430267
    • Valachis A, Polyzos NP, Nearchou A, Lind P, Mauri D, (2012) Financial relationships in economic analyses of targeted therapies in oncology. J Clin Oncol 30: 1316-1320. doi:10.1200/JCO.2011.38.6078. PubMed: 22430267.
    • (2012) J Clin Oncol , vol.30 , pp. 1316-1320
    • Valachis, A.1    Polyzos, N.P.2    Nearchou, A.3    Lind, P.4    Mauri, D.5
  • 30
    • 80053373366 scopus 로고    scopus 로고
    • Financial conflicts of interest in economic analyses in oncology
    • PubMed: 21441858
    • Jang S, Chae YK, Majhail NS, (2011) Financial conflicts of interest in economic analyses in oncology. Am J Clin Oncol 34: 524-528. PubMed: 21441858.
    • (2011) Am J Clin Oncol , vol.34 , pp. 524-528
    • Jang, S.1    Chae, Y.K.2    Majhail, N.S.3
  • 31
    • 77953024444 scopus 로고    scopus 로고
    • Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
    • doi:10.1007/s10549-010-0870-7. PubMed: 20352486
    • Jang S, Chae YK, Haddad T, Majhail NS, (2010) Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat 121: 273-279. doi:10.1007/s10549-010-0870-7. PubMed: 20352486.
    • (2010) Breast Cancer Res Treat , vol.121 , pp. 273-279
    • Jang, S.1    Chae, Y.K.2    Haddad, T.3    Majhail, N.S.4
  • 32
    • 0242659833 scopus 로고    scopus 로고
    • Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
    • doi:10.1038/sj.bjc.6601308. PubMed: 14562007
    • Hartmann M, Knoth H, Schulz D, Knoth S, (2003) Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer. 89: 1405-1408. doi:10.1038/sj.bjc.6601308. PubMed: 14562007.
    • (2003) Br J Cancer , vol.89 , pp. 1405-1408
    • Hartmann, M.1    Knoth, H.2    Schulz, D.3    Knoth, S.4
  • 33
    • 0032724035 scopus 로고    scopus 로고
    • Evaluation of conflict of interest in economic analyses of new drugs used in oncology
    • doi:10.1001/jama.282.15.1453. PubMed: 10535436
    • Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL, (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 282: 1453-1457. doi:10.1001/jama.282.15.1453. PubMed: 10535436.
    • (1999) JAMA , vol.282 , pp. 1453-1457
    • Friedberg, M.1    Saffran, B.2    Stinson, T.J.3    Nelson, W.4    Bennett, C.L.5
  • 34
    • 4944235874 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues
    • doi:10.1016/j.schres.2004.02.012. PubMed: 15474916
    • Basu A, (2004) Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res 71: 445-462. doi:10.1016/j.schres.2004.02.012. PubMed: 15474916.
    • (2004) Schizophr Res , vol.71 , pp. 445-462
    • Basu, A.1
  • 35
    • 0346366732 scopus 로고    scopus 로고
    • Quantitative analysis of sponsorship bias in economic studies of antidepressants
    • doi:10.1192/bjp.183.6.498. PubMed: 14645020
    • Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW, (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry. 183: 498-506. doi:10.1192/bjp.183.6.498. PubMed: 14645020.
    • (2003) Br J Psychiatry , vol.183 , pp. 498-506
    • Baker, C.B.1    Johnsrud, M.T.2    Crismon, M.L.3    Rosenheck, R.A.4    Woods, S.W.5
  • 36
    • 84859373020 scopus 로고    scopus 로고
    • Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review
    • doi:10.1177/0272989X11403834. PubMed: 21490308
    • Peura PK, Martikainen JA, Purmonen TT, Turunen JH, (2012) Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review. Med Decis Mak. 32: 237-245. doi:10.1177/0272989X11403834. PubMed: 21490308.
    • (2012) Med Decis Mak , vol.32 , pp. 237-245
    • Peura, P.K.1    Martikainen, J.A.2    Purmonen, T.T.3    Turunen, J.H.4
  • 37
    • 84857929499 scopus 로고    scopus 로고
    • Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review
    • doi:10.1186/cc11241. PubMed: 22405349
    • Thirugnanam S, Pinto R, Cook DJ, Geerts WH, Fowler RA, (2012) Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. Crit Care. 16: R43. doi:10.1186/cc11241. PubMed: 22405349.
    • (2012) Crit Care , vol.16
    • Thirugnanam, S.1    Pinto, R.2    Cook, D.J.3    Geerts, W.H.4    Fowler, R.A.5
  • 38
    • 33846534132 scopus 로고    scopus 로고
    • The cost-effectiveness of drug-eluting stents: a systematic review
    • PubMed: 17179219
    • Ligthart S, Vlemmix F, Dendukuri N, Brophy JM, (2007) The cost-effectiveness of drug-eluting stents: a systematic review. CMAJ. 176: 199-205. PubMed: 17179219.
    • (2007) CMAJ , vol.176 , pp. 199-205
    • Ligthart, S.1    Vlemmix, F.2    Dendukuri, N.3    Brophy, J.M.4
  • 39
    • 77949414359 scopus 로고    scopus 로고
    • Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis
    • doi:10.2165/11530530-000000000-00000. PubMed: 20222753
    • Fleurence RL, Spackman DE, Hollenbeak C, (2010) Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics. 28: 295-306. doi:10.2165/11530530-000000000-00000. PubMed: 20222753.
    • (2010) Pharmacoeconomics , vol.28 , pp. 295-306
    • Fleurence, R.L.1    Spackman, D.E.2    Hollenbeak, C.3
  • 40
    • 79953778308 scopus 로고    scopus 로고
    • Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test
    • PubMed: 21402681
    • Polyzos NP, Valachis A, Mauri D, Ioannidis JP, (2011) Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. CMAJ. 183: E337-E343. PubMed: 21402681.
    • (2011) CMAJ , vol.183
    • Polyzos, N.P.1    Valachis, A.2    Mauri, D.3    Ioannidis, J.P.4
  • 42
    • 0031690809 scopus 로고    scopus 로고
    • The effectiveness of cost-effectiveness analysis in containing costs
    • doi:10.1046/j.1525-1497.1998.00201.x. PubMed: 9798812
    • Azimi NA, Welch HG, (1998) The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 13: 664-669. doi:10.1046/j.1525-1497.1998.00201.x. PubMed: 9798812.
    • (1998) J Gen Intern Med , vol.13 , pp. 664-669
    • Azimi, N.A.1    Welch, H.G.2
  • 43
    • 27344437362 scopus 로고    scopus 로고
    • Cost effectiveness of statins in coronary heart disease
    • doi:10.1136/jech.2005.034900. PubMed: 16234419
    • Franco OH, Peeters A, Looman CW, Bonneux L, (2005) Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health. 59: 927-933. doi:10.1136/jech.2005.034900. PubMed: 16234419.
    • (2005) J Epidemiol Community Health , vol.59 , pp. 927-933
    • Franco, O.H.1    Peeters, A.2    Looman, C.W.3    Bonneux, L.4
  • 44
    • 0025729633 scopus 로고
    • Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
    • doi:10.1056/NEJM199105093241911. PubMed: 1901959
    • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. (1991) Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 324: 1362-1365. doi:10.1056/NEJM199105093241911. PubMed: 1901959.
    • (1991) N Engl J Med , vol.324 , pp. 1362-1365
    • Hillman, A.L.1    Eisenberg, J.M.2    Pauly, M.V.3    Bloom, B.S.4    Glick, H.5
  • 45
    • 0031948222 scopus 로고    scopus 로고
    • Paying the piper for pharmacoeconomic studies
    • doi:10.1177/0272989X9801800205. PubMed: 9566464
    • Neumann PJ, (1998) Paying the piper for pharmacoeconomic studies. Med Decis Mak. 18: S23-S26. doi:10.1177/0272989X9801800205. PubMed: 9566464.
    • (1998) Med Decis Mak , vol.18
    • Neumann, P.J.1
  • 46
    • 4043076368 scopus 로고    scopus 로고
    • Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination
    • doi:10.1016/j.vaccine.2004.03.001. PubMed: 15308354
    • Beutels P, (2004) Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine. 22: 3312-3322. doi:10.1016/j.vaccine.2004.03.001. PubMed: 15308354.
    • (2004) Vaccine , vol.22 , pp. 3312-3322
    • Beutels, P.1
  • 47
    • 0344237248 scopus 로고    scopus 로고
    • Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result
    • doi:10.1093/rheumatology/keg456. PubMed: 14645870
    • Welsing PM, Severens JL, Laan RF, (2003) Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result. Rheumatology (Oxf). 42: 1574-1575. doi:10.1093/rheumatology/keg456. PubMed: 14645870.
    • (2003) Rheumatology (Oxf) , vol.42 , pp. 1574-1575
    • Welsing, P.M.1    Severens, J.L.2    Laan, R.F.3
  • 48
    • 33744988779 scopus 로고    scopus 로고
    • How NICE may be outflanked
    • doi:10.1136/bmj.332.7552.1268. PubMed: 16735342
    • Ferner RE, McDowell SE, (2006) How NICE may be outflanked. BMJ. 332: 1268-1271. doi:10.1136/bmj.332.7552.1268. PubMed: 16735342.
    • (2006) BMJ , vol.332 , pp. 1268-1271
    • Ferner, R.E.1    McDowell, S.E.2
  • 49
    • 0036311575 scopus 로고    scopus 로고
    • Being economical with the truth: how to make your idea appear cost effective
    • doi:10.1136/emj.19.4.301. PubMed: 12101135
    • Goodacre S, McCabe C, (2002) Being economical with the truth: how to make your idea appear cost effective. Emerg Med J 19: 301-304. doi:10.1136/emj.19.4.301. PubMed: 12101135.
    • (2002) Emerg Med J , vol.19 , pp. 301-304
    • Goodacre, S.1    McCabe, C.2
  • 50
    • 0343471474 scopus 로고    scopus 로고
    • Language bias in randomised controlled trials published in English and German
    • doi:10.1016/S0140-6736(97)02419-7. PubMed: 9251637
    • Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, et al. (1997) Language bias in randomised controlled trials published in English and German. Lancet. 350: 326-329. doi:10.1016/S0140-6736(97)02419-7. PubMed: 9251637.
    • (1997) Lancet , vol.350 , pp. 326-329
    • Egger, M.1    Zellweger-Zähner, T.2    Schneider, M.3    Junker, C.4    Lengeler, C.5
  • 51
    • 84857342101 scopus 로고    scopus 로고
    • Promoting transparency in pharmaceutical industry-sponsored research
    • doi:10.2105/AJPH.2011.300187. PubMed: 22095335
    • Ross JS, Gross CP, Krumholz HM, (2012) Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health. 102: 72-80. doi:10.2105/AJPH.2011.300187. PubMed: 22095335.
    • (2012) Am J Public Health , vol.102 , pp. 72-80
    • Ross, J.S.1    Gross, C.P.2    Krumholz, H.M.3
  • 52
    • 34848847826 scopus 로고    scopus 로고
    • Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?
    • doi:10.1371/journal.pmed.0040286. PubMed: 17896859
    • Sismondo S, (2007) Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLOS Med 4: e286. doi:10.1371/journal.pmed.0040286. PubMed: 17896859.
    • (2007) PLOS Med , vol.4
    • Sismondo, S.1
  • 53
    • 0028074701 scopus 로고
    • The journal's policy on cost-effectiveness analyses
    • Kassirer JP, Angell M, (1994) The journal's policy on cost-effectiveness analyses. N Engl J Med. 331: 669-70.
    • (1994) N Engl J Med , vol.331 , pp. 669-670
    • Kassirer, J.P.1    Angell, M.2
  • 54
    • 0034716730 scopus 로고    scopus 로고
    • Pharmacoeconomic analyses: making them transparent, making them credible
    • doi:10.1001/jama.283.16.2158. PubMed: 10791510
    • Rennie D, Luft HS, (2000) Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 283: 2158-2160. doi:10.1001/jama.283.16.2158. PubMed: 10791510.
    • (2000) JAMA , vol.283 , pp. 2158-2160
    • Rennie, D.1    Luft, H.S.2
  • 55
    • 39449097300 scopus 로고    scopus 로고
    • Transparency of economic evaluations of health technologies
    • doi:10.2165/00019053-200826030-00002. PubMed: 18282013
    • Rovira J, (2008) Transparency of economic evaluations of health technologies. Pharmacoeconomics. 26: 181-183. doi:10.2165/00019053-200826030-00002. PubMed: 18282013.
    • (2008) Pharmacoeconomics , vol.26 , pp. 181-183
    • Rovira, J.1
  • 56
    • 84872621588 scopus 로고    scopus 로고
    • Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis
    • doi:10.1371/journal.pone.0038012. PubMed: 22666435
    • Catalá-López F, Alonso-Arroyo A, Aleixandre-Benavent R, Ridao M, Bolaños M, et al. (2012) Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis. PLOS ONE. 7: e38012. doi:10.1371/journal.pone.0038012. PubMed: 22666435.
    • (2012) PLOS ONE , vol.7
    • Catalá-López, F.1    Alonso-Arroyo, A.2    Aleixandre-Benavent, R.3    Ridao, M.4    Bolaños, M.5
  • 57
    • 79953800435 scopus 로고    scopus 로고
    • A glimpse into the black box of cost-effectiveness analyses
    • PubMed: 21402688
    • John-Baptiste AA, Bell C, (2011) A glimpse into the black box of cost-effectiveness analyses. CMAJ. 183: E307-E308. PubMed: 21402688.
    • (2011) CMAJ , vol.183
    • John-Baptiste, A.A.1    Bell, C.2
  • 58
    • 0034716729 scopus 로고    scopus 로고
    • Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme
    • doi:10.1001/jama.283.16.2116. PubMed: 10791503
    • Hill SR, Mitchell AS, Henry DA, (2000) Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 283: 2116-2121. doi:10.1001/jama.283.16.2116. PubMed: 10791503.
    • (2000) JAMA , vol.283 , pp. 2116-2121
    • Hill, S.R.1    Mitchell, A.S.2    Henry, D.A.3
  • 59
    • 22944436125 scopus 로고    scopus 로고
    • Common methodological flaws in economic evaluations
    • PubMed: 16056003
    • Drummond M, Sculpher M, (2005) Common methodological flaws in economic evaluations. Med Care. 43: 5-14. PubMed: 16056003.
    • (2005) Med Care , vol.43 , pp. 5-14
    • Drummond, M.1    Sculpher, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.